Proteasome inhibitors in the treatment of nonsmall cell lung cancer: A systematic review of clinical evidence.

Alethea Dasha Wenning ChuaThirumeninathan ThaarunHui YangAinsley Ryan Yan Bin Lee

Published in: Health science reports (2023)

Bortezomib showed some clinical promise in combination therapy but not monotherapy. It also demonstrated a manageable side effect profile. Combination regimens are of further investigation value in Phase II trials.

Keyphrases

combination therapy
phase ii
clinical trial
open label
cell therapy
machine learning
newly diagnosed
mesenchymal stem cells
study protocol
double blind
artificial intelligence